Safety and Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Healthy Subjects Aged 18 Years and Above
Clinical trial NCT06642558 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06642558
- Sponsor
- MAXVAX Biotechnology Limited Liability Company
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-11-13
- Primary completion
- 2025-06-30
- Enrollment
- 522
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.